Gilead Sciences, Inc. (NASDAQ:GILD) Stock Rated “Moderate Buy” by Sell-Side Analysts

Gilead Sciences, Inc. (NASDAQ:GILD) has been assigned an average rating of “Moderate Buy” from the twenty-nine analysts that are presently covering the company, Marketbeat.com reports. Six analysts have rated the stock with a hold rating and twenty-three have given a buy rating to the company. The average twelve-month target price among brokers that have updated their coverage on the stock in the last year is $159.81.

Several analysts recently weighed in on GILD shares. Morgan Stanley reduced their target price on shares of Gilead Sciences from $165.00 to $163.00 and set an “overweight” rating on the stock in a report on Wednesday, October 7th. Truist Financial boosted their price target on shares of Gilead Sciences from $150.00 to $158.00 and gave the stock a “buy” rating in a report on Wednesday, October 7th. Weiss Ratings raised shares of Gilead Sciences from a “hold (c-)” rating to a “hold (c)” rating in a research report on Monday, September 14th. Bank of America lifted their price objective on shares of Gilead Sciences from $168.00 to $172.00 and gave the stock a “buy” rating in a research report on Tuesday, October 20th. Finally, JPMorgan Chase & Co. lifted their price objective on shares of Gilead Sciences from $160.00 to $170.00 and gave the stock an “overweight” rating in a research report on Wednesday, October 7th.

Gilead Sciences Price Performance

GILD stock opened at $156.04 on Wednesday. The business’s 50-day moving average is $149.10 and its two-hundred day moving average is $137.84. The company has a debt-to-equity ratio of 2.03, a current ratio of 1.27 and a quick ratio of 1.09. The firm has a market capitalization of $193.48 billion, a P/E ratio of -58.44 and a beta of 0.31. Gilead Sciences has a 1 year low of $114.02 and a 1 year high of $160.51.

Gilead Sciences (NASDAQ:GILD) last announced its quarterly earnings data on Monday, August 3rd. The biopharmaceutical company reported ($6.75) EPS for the quarter, topping analysts’ consensus estimates of ($7.25) by $0.50. Gilead Sciences had a negative return on equity of 2.11% and a negative net margin of 10.64%. The business had revenue of $7.80 billion during the quarter, compared to the consensus estimate of $7.40 billion. During the same period in the previous year, the company posted $2.01 earnings per share. The business’s revenue for the quarter was up 10.6% on a year-over-year basis. Analysts anticipate that Gilead Sciences will post -0.48 earnings per share for the current fiscal year.

Gilead Sciences Announces Dividend

The firm also recently announced a quarterly dividend, which was paid on Tuesday, September 29th. Investors of record on Tuesday, September 15th were issued a $0.82 dividend. This represents a $3.28 annualized dividend and a yield of 2.1%. The ex-dividend date of this dividend was Tuesday, September 15th. Gilead Sciences’s dividend payout ratio is -122.85%.

Gilead Sciences News Summary

Here are the key news stories impacting Gilead Sciences this week:

• Positive Sentiment: Inflammation pipeline expanded: Gilead agreed to acquire PepStar Therapeutics’ investigational oral IL-23R inhibitor program, including HCXT-2001, for approximately $1.275 billion in cash. The drug is intended for inflammatory bowel disease and could be developed alone or alongside Gilead’s emvistegrast, strengthening the company’s longer-term growth prospects. Gilead to Acquire Investigational Oral IL-23R Inhibitor HCXT-2001
• Positive Sentiment: HIV development update: An ongoing study of a potential weekly oral HIV treatment adds another option to Gilead’s long-acting HIV portfolio. Positive clinical progress could support the company’s dominant HIV franchise and future revenue durability. Gilead’s Weekly HIV Pill Study Adds Long-Acting Firepower
• Positive Sentiment: Oncology collaboration: BioNTech and Gilead will test Gilead’s sacituzumab govitecan with BioNTech’s pumitamig in a global Phase 3 trial for advanced triple-negative breast cancer. The collaboration may improve the commercial potential of Gilead’s oncology platform, although clinical success remains uncertain. BioNTech, Gilead to Test Drug Combination
• Positive Sentiment: Favorable analyst and earnings expectations: TD Cowen reiterated a Buy view, while analysts indicated that Gilead could beat expectations in its upcoming quarterly report. Such forecasts support sentiment, though they are not guarantees of results. Gilead Sciences Receives a Buy from TD Cowen
• Neutral Sentiment: Gilead plans to present new data on rare liver diseases at The Liver Meeting 2026. The presentations could generate future catalysts, but no immediate clinical results were reported. Gilead to Present New Liver-Disease Data
• Negative Sentiment: Legal overhang: Gilead will pay $45 million to settle Texas Medicaid claims alleging unlawful incentives to encourage providers to prescribe its medicines. The financial cost is modest relative to Gilead’s size, but the settlement adds regulatory and reputational risk. Gilead Sciences to Pay $45 Million in Texas Medicaid Settlement

Insider Buying and Selling

In other Gilead Sciences news, Director Anthony Welters sold 18,000 shares of Gilead Sciences stock in a transaction dated Wednesday, August 26th. The stock was sold at an average price of $148.62, for a total transaction of $2,675,160.00. Following the completion of the sale, the director directly owned 12,894 shares of the company’s stock, valued at $1,916,306.28. The trade was a 58.26% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Johanna Mercier sold 3,000 shares of Gilead Sciences stock in a transaction dated Thursday, October 15th. The stock was sold at an average price of $156.22, for a total value of $468,660.00. Following the sale, the insider directly owned 113,684 shares of the company’s stock, valued at $17,759,714.48. This trade represents a 2.57% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 111,000 shares of company stock valued at $15,877,860 over the last 90 days. 0.30% of the stock is currently owned by corporate insiders.

Institutional Investors Weigh In On Gilead Sciences

Institutional investors have recently added to or reduced their stakes in the business. Apollon Wealth Management LLC boosted its holdings in Gilead Sciences by 2.5% in the third quarter. Apollon Wealth Management LLC now owns 39,561 shares of the biopharmaceutical company’s stock valued at $5,897,000 after purchasing an additional 976 shares in the last quarter. Kingswood Wealth Advisors LLC increased its stake in Gilead Sciences by 9.6% in the third quarter. Kingswood Wealth Advisors LLC now owns 11,709 shares of the biopharmaceutical company’s stock valued at $1,745,000 after purchasing an additional 1,023 shares during the last quarter. Royal Palms Capital LLC acquired a new stake in Gilead Sciences during the third quarter worth approximately $207,000. Revolve Wealth Partners LLC raised its holdings in Gilead Sciences by 2.2% during the third quarter. Revolve Wealth Partners LLC now owns 5,592 shares of the biopharmaceutical company’s stock worth $833,000 after purchasing an additional 119 shares in the last quarter. Finally, Radnor Capital Management LLC acquired a new stake in Gilead Sciences during the third quarter worth approximately $237,000. Hedge funds and other institutional investors own 83.67% of the company’s stock.

Gilead Sciences Company Profile

Gilead Sciences, Inc is a biopharmaceutical company that discovers, develops and commercializes medicines for serious and life-threatening diseases. The company is best known for its HIV treatments, including Biktarvy, Descovy, Genvoya and Truvada, as well as therapies for chronic hepatitis B and hepatitis C. Its portfolio also includes Veklury (remdesivir), an antiviral treatment for COVID-19.

Gilead has expanded into oncology and cell therapy through products such as Trodelvy and the CAR T-cell therapies Yescarta and Tecartus, which are developed and marketed through its Kite subsidiary.